• U.S. FDA approval of Talicia® for the treatment of Helicobacter pylori infection in adults
• Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to
commercialize Aemcolo® in the U.S. for travelers’ diarrhea
• Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in
Q4/2019 and Q1/2020, respectively
• Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo
Pharmaceuticals.
Technically, as long it above 6.1, target it 6.7 and 7 .
Good-luck
Not for a suggestion.
• Strategic partnership with Cosmo Pharmaceuticals, including investment of $36.3 million and exclusive rights to
commercialize Aemcolo® in the U.S. for travelers’ diarrhea
• Accelerating expansion of commercial sales team in the U.S. ahead of planned launches of Aemcolo® and Talicia® in
Q4/2019 and Q1/2020, respectively
• Debt-free balance sheet with approximately $59 million as of October 22, 2019 following the investment by Cosmo
Pharmaceuticals.
Technically, as long it above 6.1, target it 6.7 and 7 .
Good-luck
Not for a suggestion.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.
Penafian
Maklumat dan penerbitan adalah tidak dimaksudkan untuk menjadi, dan tidak membentuk, nasihat untuk kewangan, pelaburan, perdagangan dan jenis-jenis lain atau cadangan yang dibekalkan atau disahkan oleh TradingView. Baca dengan lebih lanjut di Terma Penggunaan.